← Back to Search

Cancer Vaccine

DPX-Survivac + Hormone/Radiation/Cyclophosphamide for Breast Cancer

Phase 1
Waitlist Available
Led By Sasha Stanton, MD
Research Sponsored by Providence Health & Services
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Women with resectable, non-metastatic breast cancer that is >1 cm, hormone receptor positive, HER2 negative, Ki67>10%
Patients must be at least 18 years of age
Must not have
Patients unable to receive an aromatase inhibitor
Previous breast cancer, tamoxifen, or aromatase inhibitor use
Timeline
Screening 3 weeks
Treatment Varies
Follow Up throughout the study day 1, day 8, day 15, day 29, day 36, week 7-9, week 11, and 6 months post-surgery
Awards & highlights
All Individual Drugs Already Approved
Approved for 20 Other Conditions
No Placebo-Only Group

Summary

This trial tests a cancer vaccine combined with radiation or low-dose chemotherapy, plus hormone therapy, in women with certain types of breast cancer. The goal is to boost the immune system, reduce tumor recurrence, and slow tumor growth.

Who is the study for?
This trial is for post-menopausal women with resectable, non-metastatic breast cancer that's hormone receptor positive and HER2 negative. Participants should have a tumor larger than 1 cm, be at least 18 years old with good performance status, and have adequate organ function. They must not have had previous breast cancer treatments or certain other conditions.
What is being tested?
The study tests the safety of neoadjuvant aromatase inhibitor therapy combined with DPX-Survivac alone, DPX-Survivac plus radiation (10Gy x2), or DPX-Survivac with cyclophosphamide (50mg). Each participant will also take letrozole (2.5mg daily) during the six-week pre-surgery treatment phase.
What are the potential side effects?
Potential side effects may include reactions to vaccine components like DPX-Survivac, hormonal changes from letrozole, blood count changes from cyclophosphamide, and skin irritation from radiation. The exact side effects will vary depending on the treatment arm.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My breast cancer is operable, not spread, larger than 1 cm, hormone-sensitive, HER2 negative, and has a high growth rate.
Select...
I am 18 years old or older.
Select...
I am fully active or can carry out light work.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I cannot take aromatase inhibitors for my condition.
Select...
I have had breast cancer or used tamoxifen or aromatase inhibitors before.
Select...
I have had radiation therapy on my breast before.
Select...
I am not pregnant and I am post-menopausal.
Select...
I have a history of HIV, hepatitis B, or hepatitis C.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~throughout the study day 1, day 8, day 15, day 29, day 36, week 7-9, week 11, and 6 months post-surgery
This trial's timeline: 3 weeks for screening, Varies for treatment, and throughout the study day 1, day 8, day 15, day 29, day 36, week 7-9, week 11, and 6 months post-surgery for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of participants without the following safety events: TASAEs, persistent grade III/IV TAAEs, or toxicity-related delays in curative-intent surgery. Toxicity graded by CTCAE v5.0 and monitoring of AEs performed per FDA and NCI guidelines.
Secondary study objectives
Immunogenicity of each therapeutic arm GEO-Mx digital spatial profiler
Immunogenicity of each therapeutic arm IFN-γ ELISPOT

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 20 Other Conditions
This treatment demonstrated efficacy for 20 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Arm C: DPX-Survivac, Letrozole, cyclophosphamideExperimental Treatment3 Interventions
Letrozole 2.5 mg po daily, cyclophosphamide 50 mg po BID, DPX-Survivac 0.25 mL SC week 2 and Week 5
Group II: Arm B: DPX-Survivac, Letrozole, RadiationExperimental Treatment3 Interventions
Letrozole 2.5 mg po daily, XRT 10 Gy x 2, DPX-Survivac 0.25 mL SC week 2 and Week 5
Group III: Arm A: DPX-Survivac, LetrozoleExperimental Treatment2 Interventions
Letrozole 2.5 mg po daily, DPX-Survivac 0.25 mL SC week 2 and Week 5
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
DPX-Survivac
2013
Completed Phase 2
~90
Letrozole
FDA approved
Cyclophosphamide
FDA approved

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Breast cancer treatments often include immunotherapy, hormone therapy, and chemotherapy. Immunotherapy, such as DPX-Survivac, targets proteins like survivin to stimulate the immune system to attack cancer cells, offering a personalized approach to treatment. Hormone therapies, like aromatase inhibitors, reduce estrogen levels to slow the growth of hormone receptor-positive breast cancers. Chemotherapy uses cytotoxic drugs to kill rapidly dividing cancer cells. These treatments are crucial as they provide multiple strategies to target cancer cells, improving patient outcomes and offering options tailored to individual tumor characteristics.

Find a Location

Who is running the clinical trial?

Providence Health & ServicesLead Sponsor
124 Previous Clinical Trials
823,757 Total Patients Enrolled
6 Trials studying Breast Cancer
4,602 Patients Enrolled for Breast Cancer
Sasha Stanton, MDPrincipal InvestigatorProvidence Health & Services

Media Library

DPX-Survivac (Cancer Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT04895761 — Phase 1
Breast Cancer Research Study Groups: Arm A: DPX-Survivac, Letrozole, Arm B: DPX-Survivac, Letrozole, Radiation, Arm C: DPX-Survivac, Letrozole, cyclophosphamide
Breast Cancer Clinical Trial 2023: DPX-Survivac Highlights & Side Effects. Trial Name: NCT04895761 — Phase 1
DPX-Survivac (Cancer Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04895761 — Phase 1
~1 spots leftby Dec 2025